Investing.com - Supernus reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations. Supernus announced earnings per share of...
Supernus Pharma (SUPN) reported Q3 EPS of $0.03, $0.32 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $177.35 million versus the consensus estimate of...
Supernus Pharmaceuticals (NASDAQ:SUPN), Inc. SUPN announced that the FDA approved its pipeline candidate, SPN-812, (viloxazine extended-release capsules) for the treatment of...
Supernus Pharmaceuticals (NASDAQ:SUPN) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of...
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. It is also developing a range of CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced Parkinson's disease (PD).
|Average||41.50 (+1.07% Upside)|
|No. of Analysts||4|